KROS Stock Analysis: Keros Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 231m USD | 12M Return: -23.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 3.28M
Qual. Beats: 0
Rev. Trend: 99.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Keros Therapeutics is a clinical-stage biopharmaceutical company based in Lexington, Massachusetts, that develops therapeutics for disorders linked to dysfunctional signaling of the transforming growth factor-beta (TGF-β) family of proteins. The company has two lead candidates: rinvatercept, a ligand trap in Phase 1 trials for Duchenne Muscular Dystrophy and Amyotrophic Lateral Sclerosis, and elritercept, a TGF-β pathway inhibitor in Phase 3 trials for Myelodysplastic Syndromes and Phase 2 trials for Myelofibrosis. Keros generates revenue primarily through collaboration and license agreements with Hansoh (Shanghai) Healthtech and Takeda Pharmaceuticals, which support the development and commercialization of elritercept. As a clinical-stage biotech with no approved products on the market, Keros relies on these partnerships and capital markets funding to advance its pipeline, and trades as a micro-cap stock following its 2020 IPO on NASDAQ.
- Elritercept Phase 3 MDS data readout is key stock catalyst
- Cash burn and potential dilution pressure micro-cap shares
- Takeda and Hansoh partnerships provide milestone payments
| Net Income: -85.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.19 > 0.02 and ΔFCF/TA -24.17 > 1.0 |
| NWC/Revenue: 837.3% < 20% (prev 335.4%; Δ 501.9% < -1%) |
| CFO/TA -0.18 > 3% & CFO -57.2m > Net Income -85.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 22.62 > 1.5 & < 3 |
| Outstanding Shares: last quarter (37.9m) vs 12m ago -7.71% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 6.05% > 50% (prev 27.37%; Δ -21.32% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.89 (Total Current Assets 290.7m - Total Current Liabilities 12.9m) / Total Assets 312.3m |
| B: -1.62 (Retained Earnings -505.5m / Total Assets 312.3m) |
| C: -0.16 (EBIT TTM -90.3m / Avg Total Assets 548.4m) |
| D: 10.71 (Book Value of Equity 285.6m / Total Liabilities 26.7m) |
| Altman-Z'' = 10.70 = AAA |
| DSRI: 0.99 (Receivables 2.96m/19.4m, Revenue 33.2m/214.7m) |
| GMI: 1.04 (GM 99.40% / 95.27%) |
| AQI: 1.90 (AQ_t 0.00 / AQ_t-1 0.00) |
| SGI: 0.15 (Revenue 33.2m / 214.7m) |
| TATA: -0.09 (NI -85.1m - CFO -57.2m) / TA 312.3m) |
| Beneish M = -3.07 (Cap -4..+1) = AA |
As of July 14, 2026, the stock is trading at USD 11.10 with a total of 250,130 shares traded. Over the past week, the price has changed by +0.63%, over one month by +8.40%, over three months by -0.45% and over the past year by -23.82%.
Current recommended Stop Loss: 10.10 (which is 9% or 1.8 ATR below the current price).
Keros Therapeutics has received a consensus analysts rating of 3.92. Therefore, it is recommended to buy KROS.
- StrongBuy: 5
- Buy: 2
- Hold: 6
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 21.8 | 96.7% |
P/E Forward = 48.7805
P/S = 6.9488
P/B = 0.7802
Revenue TTM = 33.2m USD
EBIT TTM = -90.3m USD
EBITDA TTM = -88.7m USD
Long Term Debt = 13.8m USD (estimated: total debt 16.3m - short term 2.50m)
Short Term Debt = 2.50m USD (from shortTermDebt, last quarter)
Debt = 16.3m USD (from shortLongTermDebtTotal, last quarter) (leases 16.3m already included)
Net Debt = -265.2m USD (calculated: Debt 16.3m - CCE 281.5m)
Enterprise Value = 230.6m USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = unknown (Ebit TTM -90.3m / Interest Expense TTM 0.0)
EV/FCF = -3.96x (Enterprise Value 230.6m / FCF TTM -58.3m)
FCF Yield = -25.26% (FCF TTM -58.3m / Enterprise Value 230.6m)
FCF Margin = -175.6% (FCF TTM -58.3m / Revenue TTM 33.2m)
Net Margin = -256.6% (Net Income TTM -85.1m / Revenue TTM 33.2m)
Gross Margin = unknown ((Revenue TTM 33.2m - Cost of Revenue TTM 1.57m) / Revenue TTM)
Tobins Q-Ratio = 0.74 (Enterprise Value 230.6m / Total Assets 312.3m)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 16.3m)
Taxrate = 5.31% (4.88m / 91.9m)
NOPAT = -85.5m (EBIT -90.3m * (1 - 5.31%)) [loss with tax shield]
Current Ratio = 22.62 (Total Current Assets 290.7m / Total Current Liabilities 12.9m)
Debt / Equity = 0.06 (Debt 16.3m / totalStockholderEquity, last quarter 285.6m)
Debt / EBITDA = 2.99 (negative EBITDA) (Net Debt -265.2m / EBITDA -88.7m)
Debt / FCF = 4.55 (negative FCF - burning cash) (Net Debt -265.2m / FCF TTM -58.3m)
Total Stockholder Equity = 499.8m (last 4 quarters mean from totalStockholderEquity)
RoA = -15.53% (Net Income -85.1m / Total Assets 312.3m)
RoE = -17.04% (Net Income TTM -85.1m / Total Stockholder Equity 499.8m)
RoCE = -17.58% (EBIT -90.3m / Capital Employed (Equity 499.8m + L.T.Debt 13.8m))
RoIC = -28.48% (negative operating profit) (NOPAT -85.5m / Invested Capital 300.3m)
WACC = 8.89% (E(230.6m)/V(246.9m) * Re(9.52%) + D(16.3m)/V(246.9m) * Rd(0.0%) * (1-Tc(0.05)))
Discount Rate = 9.52% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 71.74 | Cagr: 10.69%
[DCF] Fair Price = unknown (Cash Flow -58.3m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.35 | # QB: 0
Revenue Correlation: 99.65 | Revenue CAGR: 3.92k% | SUE: -0.02 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.24 | Chg30d=-6.88% | Revisions=-57% | Analysts=5
EPS next Quarter (2026-09-30): EPS=-1.30 | Chg30d=-3.84% | Revisions=-57% | Analysts=5
EPS current Year (2026-12-31): EPS=-5.19 | Chg30d=-10.97% | Revisions=-57% | GrowthEPS=-325.5% | GrowthRev=-98.3%
EPS next Year (2027-12-31): EPS=-5.59 | Chg30d=-10.69% | Revisions=-29% | GrowthEPS=-7.8% | GrowthRev=+344.7%
[Analyst] Revisions Ratio: -74% (up=1, down=15)